How to Monitor Zuranolone Response in Postpartum Depression
How should clinicians assess whether zuranolone is improving postpartum depression when anxiety and insomnia symptoms are also present?
Women with postpartum depression commonly present with anxiety and sleep disturbance in addition to depressed mood, and these symptoms are associated with more severe illness, slower improvement, and poorer functioning. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression provides a structured way to track whether a short oral course is improving depression, anxiety, insomnia, and patient-perceived functioning over the first 45 days.
-
Confirm that the patient matches the studied postpartum depression population
Use this monitoring approach for adult women 18 to 45 years old who are within 6 months postpartum and have postpartum depression defined as a DSM-5 major depressive episode with onset in the third trimester or within 4 weeks postpartum. In the trial, baseline depression severity was high, with HDRS-17 total score 26 or greater, so the reported response pattern is drawn from a population with severe symptoms.
-
Document concurrent antidepressant use before starting assessment
Record whether the patient is already receiving psychotropic medication intended to treat depressive symptoms. In the trial, such treatment was allowed only if the dose had been stable for at least 30 days before day 1 and remained unchanged through day 15, so early outcome interpretation was anchored to a stable background regimen.
-
Set the treatment and follow-up timeline
Monitor response around a once-daily 14-day course of oral zuranolone 30 mg, with assessments during treatment and after treatment ends. The study evaluated outcomes at days 3, 8, 15, 21, and 45, with day 45 occurring 30 days after treatment cessation.
-
Measure depressive and anxiety symptoms together
Track dual remission rather than depression alone by combining a depression scale with HARS. The article defined concurrent remission as HARS total score 7 or less plus either HDRS-17 total score 7 or less or MADRS total score 10 or less, and this was the main framework used to judge whether both symptom domains improved at the same time.
-
Look for early dual remission by day 3 and confirm at day 15
Assess for concurrent remission as early as day 3 because separation from placebo was seen at that first postbaseline time point. Using HDRS-17 7 or less plus HARS 7 or less, concurrent remission occurred in 18.9% of women receiving zuranolone versus 2.7% with placebo at day 3, and 40.5% versus 19.2% at day 15.
-
Assess anxiety-specific response with clinician-rated and patient-reported tools
Follow anxiety symptoms with HARS, the HDRS-17 Anxiety/Somatization subscale, and, if using a patient-reported postpartum measure, the EPDS-3A subscale. The study defined anxiety response as at least 50% reduction from baseline total score on HARS, HDRS-17 Anxiety/Somatization, or EPDS-3A, and at day 15 HARS response was 71.6% with zuranolone versus 49.3% with placebo while HDRS-17 Anxiety/Somatization response was 68.9% versus 46.6%.
-
Track insomnia symptoms on the same schedule
Include sleep symptom monitoring because insomnia improvement was evaluated separately from mood and anxiety outcomes. The article used the HDRS-17 insomnia subscale, MADRS item 4 for reduced sleep, and EPDS item 7 for difficulty sleeping, with nominally significant benefits for zuranolone versus placebo at all measured time points on HDRS-17 insomnia, at all time points except day 21 on MADRS reduced sleep, and at day 45 on EPDS difficulty sleeping.
-
Check whether benefits persist after the 14-day course ends
Do not stop outcome assessment when treatment stops; reassess at day 45 to determine whether gains are maintained. Concurrent remission remained higher with zuranolone at day 45, reaching 52.1% versus 23.2% by HDRS-17/HARS criteria and 53.4% versus 26.1% by MADRS/HARS criteria.
-
Identify sustained remission across days 15 and 45
Classify response as sustained when remission or response is present at both day 15 and day 45. In the study, sustained concurrent remission favored zuranolone using either HDRS-17/HARS criteria with an odds ratio of 6.2 or MADRS/HARS criteria with an odds ratio of 3.7, showing that durability can be assessed with repeated paired time points rather than a single endpoint.
-
Add patient-reported functional health to the response assessment
Evaluate whether symptom change is accompanied by improved functioning and well-being using SF-36v2. At day 45, women receiving zuranolone showed greater improvement than placebo in Social Functioning, Mental Health, Physical Functioning, Role Physical, Bodily Pain, and the Mental Component Summary score, so recovery should be judged beyond mood scores alone.
Clinical Considerations
- These analyses of concurrent remission, insomnia, and several other outcomes were exploratory or post hoc and were not controlled for multiplicity.
- The findings may not generalize fully outside a clinical trial because the study used strict inclusion and exclusion criteria.
- The monitoring framework comes from a population with severe postpartum depression defined by baseline HDRS-17 total score of at least 26.
- The brief study duration and relatively small sample limit conclusions about delayed adverse events, uncommon adverse events, and subgroup effects.
Bottom Line
When using zuranolone for postpartum depression with prominent anxiety or insomnia, assess depression, anxiety, sleep, and functioning together at days 3, 15, and 45 because clinically meaningful dual improvement may appear within 3 days and persist after the 14-day course ends.
